ClinicalTrials.gg
CompletedNCT06228560Updated Oct 21, 2026

Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

A Phase 2 interventional study of LP-003 and Placebo in Chronic Spontaneous Urticaria, sponsored by Longbio Pharma. Completed at 17 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Longbio Pharma · Phase 2, Interventional, and Treatment

Updated Oct 21, 2026Study completion moved3 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Chronic Urticaria with a site in China — 16 open to participants now, 20 under way, 5 of them phase 3. Chronic Urticaria · China.

Enrollment
9th of 30
202 · median 110
Started
2024
with 6 others
Phase 2
7 of 34
6 open now
Registered
11th of 34
by date
Lead sponsor
3 of 34
Longbio Pharma

Among the 34 studies in Chronic Urticaria with a site in China, this one is the 9th largest by enrollment of the 30 interventional ones that give a count, is one of 7 that started in 2024, is one of 7 in phase 2, and was the 11th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

16 of the 34 studies in Chronic Urticaria with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Chronic Urticaria with a site in China, or all of them as a file.
02

Study summary

The study is a Phase II, multicenter, randomized, double-blind study to evaluatethe efficacy and safety of LP-003 administered subcutaneously as an add-on therapy for the treatment of adult patients aged 18-75 who have been diagnosed with refractory CSU and who remain symptomatic despitestandard-dose H1 antihistamine treatment.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 75 years at the screening period.
  2. Presence of wheals with itching for ≥ 6 weeks prior to randomization. At the screening visit, subjects had taken double or more than the approved dose, or a combination of two or more H1 antihistamines for the treatment of chronic spontaneous urticaria for at least 2 weeks. Within the 7 days preceding randomization, the Urticaria Activity Score 7 (UAS7) was ≥16 (range 0-42), Itch Severity Score 7 (ISS7) was ≥8 (range 0-21), at least one UAS (range 0-6) was ≥4 on any screening visit day, and there must be a current record of medication use.
  3. Subjects must not miss more than one diary record (morning or night) within 7 days prior to randomization (day 1), and are willing and able to complete daily symptom electronic diary records during the study period;
  4. Male participants and their partners or female participants must agree to take one or more non pharmacological measures (such as complete abstinence, contraceptive ring, partner ligation, etc.) during the trial period and within 6 months after the end of the trial and have no plans for sperm or egg donation.
  5. Agree to participate in this clinical trial and voluntarily sign an form.

Exclusion criteria

Exclusion Criteria:

  1. The subject has a primary or sole trigger for chronic urticaria (chronic Induced urticaria), including artificial urticaria (symptomatic skin scratch disease), cold, heat, sun, pressure, delayed pressure, water, cholinergic, or contact urticaria;
  2. Other medical conditions accompanied by symptoms of urticaria or angioedema including, but not limited to, urticarial vasculitis, pigmented urticaria, erythema multiforme, mastocytosis, hereditary urticaria, or drug-induced urticaria;
  3. Any other dermatologic condition with chronic itching, such as atopic dermatitis, herpetic pemphigoid, herpetic dermatitis, senile itching, or psoriasis, which in the judgment of the Investigator may affect the evaluation of the study and the results of the study;
  4. Subjects with conditions such as (but not limited to) unstable ischemic heart disease, Class III/IV left ventricular failure, cardiac arrhythmias, uncontrolled hypertension, cerebrovascular disease, neurodegenerative, or other neurological disorders, uncontrolled hypothyroidism and hyperthyroidism and other disorders, hypokalemia, hyper adrenergic state; past diagnosis of (other than basal cell carcinoma or squamous cell skin cancer); history of myocardial infarction within 12 months prior to screening;
  5. Acute active infections requiring treatment at screening, including but not limited to, pulmonary infections, tuberculosis;
  6. Positive surface antigen or hepatitis B core antibody (except for HBV-DNA testing below the lower limit of the research center's test) at screening; positive virus antibody, (HIV) antibody, and anti-syphilis helical antibody (TP-Ab) (except for those who are negative for RPR or TRUST);
  7. Clinically significant cardiovascular, neurological, psychiatric, metabolic, hepatic, or other abnormalities identified during the Screening Period that may affect the interpretation of the study results and/or the safety of the subject;
  8. Comorbid neurological or psychiatric disorders that prevent or prevent cooperation; patients with disabilities as defined by law (blindness, deafness, mute, mental retardation, psychiatric disorders, etc.);
  9. Major surgery within 8 weeks prior to screening or surgery planned during the study period;
  10. Evidence of historical or ongoing alcohol or substance abuse in the 6 months prior to screening;
  11. Poor compliance, such as low medication adherence, inability to accurately complete a diary card, or use of prohibited medications;
  12. Pregnant women, nursing mothers, or those with recent birth plans;
  13. Patients who have participated in clinical trials of other drugs within the last 3 months;
  14. Those who are considered by the investigator to be unfit to participate in the clinical trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    LP-003 group 1

    Participants received LP-003 subcutaneously during the 24-week treatment period

    Biological: LP-003

  • Experimental
    LP-003 group 2

    Participants received LP-003 subcutaneously during the 24-week treatment period

    Biological: LP-003

  • Experimental
    LP-003 group 3

    Participants received LP-003 subcutaneously during the 24-week treatment period

    Biological: LP-003

  • Active comparator
    Omalizumab

    Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24-week treatment period

    Biological: Omalizumab

  • Placebo comparator
    Placebo

    Participants received placebo subcutaneously every 4 weeks during the 24-week treatment period

    Biological: Placebo

Interventions

  • BiologicalLP-003

    Liquid in vial

  • BiologicalPlacebo

    Liquid in vial

  • BiologicalOmalizumab

    Liquid in vial

06

What researchers measure

Primary outcomes

  1. The proportion of participants achieving complete absence of wheals and itching (UAS7 = 0) at week 12

    Time frame: Week 12

Secondary outcomes

  1. The incidence of adverse events during the study

    Time frame: 40 weeks

  2. The proportion of participants with no hives (HSS7 = 0) at week 4, 8, 12, 16, 20, 24, 32, and 40

    Time frame: Week 4, 8, 12, 16, 20, 24, 32, and 40

  3. The proportion of participants achieving complete absence of wheals and itching (UAS7 = 0) at week 4, 8, 16, 20, 24, 32, and 40

    Time frame: Week 4, 8, 16, 20, 24, 32, and 40

  4. The proportion of participants achieving complete absence of angioedema (AAS7 = 0) at week 4, 8, 12, 16, 20, 24, 32, and 40

    Time frame: Week 4, 8, 12, 16, 20, 24, 32, and 40

  5. The proportion of participants with controlled disease activity (UAS7 ≤ 6) at week 4, 8, 12, 16, 20, 24, 32, and 40

    Time frame: Week 4, 8, 12, 16, 20, 24, 32, and 40

  6. Change From Baseline in UAS7, HSS7, ISS7, AAS7 at week 4, 8, 12, 16, 20, 24, 32, and 40

    Time frame: Baseline and week 4, 8, 12, 16, 20, 24, 32, and 40

  7. Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at week 4, 8, 12, 16, 20, 24, 32, and 40

    Time frame: Baseline and week 4, 8, 12, 16, 20, 24, 32, and 40

  8. Blood concentrations of LP-003, free IgE, total IgE, anti-drug antibodies (ADA), and neutralizing antibodies (Nab) during the study

    Time frame: 40 weeks

07

Study locations

17 sites
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality, China
  • Peking University Third Hospital
    Beijing, Beijing Municipality, China
  • The First Affiliated Hospital of China Medical University
    Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian, China
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong, China
  • The Second Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • The Second XiangYa Hospital of Central South University
    Changsha, Hunan, China
  • Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College
    Nanjing, Jiangsu, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning, China
  • Shanghai Skin Disease Hospital
    Shanghai, Shanghai Municipality, China
  • the Second Affiliated Hospital of Xi'an Jiaotong University
    Xi’an, Shanxi, China
  • Hangzhou First People's Hospital
    Hangzhou, China
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, China
  • Wuhan NO.1 Hospital
    Wuhan, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Apr 2025, 14 months.

Of 31 phase 2 interventional studies under Chronic Urticaria, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 14 months is below that.

Completion moved once since we started tracking on Sep 25, 2026: Nov 2025 → Oct 2025, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2024
First posted
Jan 29, 2024
StartActual
Jan 26, 2024
Primary completionActual
Apr 17, 2025
CompletionActual
Oct 16, 2025was Nov 2025
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites removed
Show 3 removed
  • The First Hospital of Peking University · Beijing, China
  • The First Affiliated Hospital of PLA Army Medical University · Chongqing, China
  • Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine · Shanghai, China
Oct 21, 2026
Study completion
Nov 14, 2025→Oct 16, 2025
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    3 sites removed
    Show 3 removed
    • The First Hospital of Peking University · Beijing, China
    • The First Affiliated Hospital of PLA Army Medical University · Chongqing, China
    • Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine · Shanghai, China
    Study completion Nov 14, 2025→Oct 16, 2025
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06228560
Lead sponsor
Longbio Pharma
Responsible party
Sponsor
First posted
Jan 29, 2024
Start date
Jan 26, 2024
Primary completion
Apr 17, 2025
Completion
Oct 16, 2025
Last update
Oct 21, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LP-003

Start the discussion